JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.